Intriguingly, exploratory post hoc subgroup analysis in the FERGI study suggested improvement in PFS in patients with ER+ and PgR+ tumours treated with pictilisib plus fulvestrant (median of 7.2 months in the combination arm versus 3.7 months in the control arm)17. The gene discussed is PGR; the disease is neoplasm.